Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up Following Analyst Upgrade

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s share price gapped up prior to trading on Tuesday after Royal Bank Of Canada upgraded the stock from a hold rating to a moderate buy rating. The stock had previously closed at $11.31, but opened at $11.93. Telix Pharmaceuticals shares last traded at $11.98, with a volume of 100,454 shares changing hands.

A number of other equities analysts also recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Monday, September 14th. Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Tuesday, September 15th. Finally, Weiss Ratings upgraded shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $20.40.

Trending Headlines about Telix Pharmaceuticals

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: RBC upgraded Telix from “hold” to “moderate buy,” signaling improved confidence in the company’s outlook following the recent sell-off. TickerReport coverage of RBC upgrade
• Positive Sentiment: The proposed ITM combination would create a larger radiopharmaceutical company with greater access to radioisotope production, supply capabilities and development assets. Management and industry coverage characterize the deal as a move to build a global sector leader. Telix and ITM merger announcement
• Neutral Sentiment: ASX waivers related to the timing of shares issued as acquisition consideration help facilitate the transaction, but also highlight that the deal involves equity issuance and complex closing requirements. Telix’s merger call provided additional details on the transaction and rationale. Yahoo Finance ASX preview
• Negative Sentiment: Shares fell sharply after investors focused on the acquisition’s size, funding and dilution risks. Reported transaction values range from approximately $1.65 billion on a cash- and debt-free basis to as much as $2.35 billion, while other coverage cites a higher value including broader deal considerations. Investors may also be concerned about integration execution, leverage and whether the expected strategic benefits justify the price. RTTNews report on Telix share decline

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TLX. Bank of America Corp DE increased its holdings in Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after purchasing an additional 8,423 shares during the last quarter. XY Capital Ltd acquired a new position in shares of Telix Pharmaceuticals during the 1st quarter worth about $120,000. Private Advisor Group LLC grew its position in shares of Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after buying an additional 128,070 shares during the period. Hennion & Walsh Asset Management Inc. bought a new stake in shares of Telix Pharmaceuticals in the 2nd quarter valued at about $1,731,000. Finally, Lazard Asset Management LLC raised its position in shares of Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after acquiring an additional 39,400 shares during the period.

Telix Pharmaceuticals Stock Performance

The business’s 50-day moving average is $11.30 and its two-hundred day moving average is $10.38. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.